NAP mechanisms of neuroprotection

Journal of Molecular Neuroscience

Volumn 24, Issue 1, 2004, Pages 67-72

  Gozes, Illana ^a   Steingart, Ruth A ^a   Spier, Avron D ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Allon Therapeutics Inc   (United States)

Author keywords

Neuroprotection; Peptides

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; ALCOHOL; AMYLOID BETA PROTEIN; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; BENZALKONIUM CHLORIDE; BRAIN PROTEIN; CD11B ANTIGEN; CELL PROTEIN; CITRIC ACID; CYCLIC GMP; DISODIUM HYDROGEN PHOSPHATE; DRUG VEHICLE; GLUCOSE; NEUROPROTECTIVE AGENT; PROTEIN P53; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NAPVSIPQ PEPTIDE; OLIGOPEPTIDE;

ANIMAL CELL; APOPTOSIS; CELL MEMBRANE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; EMBRYOTOXICITY; EXTRACELLULAR SPACE; INFLAMMATION; INTRACELLULAR SPACE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PEPTIDE SYNTHESIS; PROTEIN AGGREGATION; PROTEIN FOLDING; RAT; SIGNAL TRANSDUCTION; ALZHEIMER DISEASE; ANIMAL; ARTICLE; BRAIN; BRAIN ISCHEMIA; CELL STRAIN; DOWN REGULATION; DRUG EFFECT; ENCEPHALITIS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; BRAIN; BRAIN ISCHEMIA; CYCLIC GMP; DOWN-REGULATION; ENCEPHALITIS; MACROPHAGE-1 ANTIGEN; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; OXIDATIVE STRESS; PC12 CELLS; RATS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16544395626     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:24:1:067     Document Type: Conference Paper

References (31)

1. Ashur-Fabian O., Giladi E., Furman S., Steingart R. A., Wollman Y., Fridkin M., et al. (2001) Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neurosci. Lett. 307, 167-170.
2. Ashur-Fabian O., Segal-Ruder Y., Skutelsky E., Brenneman D.E., Steingart R. A., Giladi E., and Gozes I. (2003). The effect of the novel peptide NAPVISPQ on the aggregation of the beta-amyloid peptide. Peptides 24, 1413-1423.
3. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283-1293.
4. Beni-Adani L., Gozes I., Cohen Y., Assaf Y., Steingart R. A., Brenneman D. E., et al. (2001) A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injured mice. J. Pharmacol. Exp. Ther. 296, 57-63.
5. Gozes I., and Brenneman D. E. (2000) A new concept in neuroprotection. J. Mol. Neurosci. 14, 61-68.
6. Gozes I., and Spier A. (2002) Peptides as drug targets in Alzheimer's disease. Drug Dev. Res. 56, 475-481.
7. Gozes I., Alcalay R., Giladi E., Pinhasov A., Furman S., and Brenneman D. E. (2002a) NAP accelerates the performance of normal rats in the water maze. J. Mol. Neurosci. 19, 167-170.
8. Gozes I., Giladi E., Pinhasov A., Bardea A., and Brenneman D. E. (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293, 1091-1098.
9. Gozes I., Giladi E., Pinhasov A., Furman S., Romano J., Steingart R. A., Rubinraut S., and Fridkin M. (2002b) Intranasal delivery of bioactive peptides or peptide analogues enhances spatial memory and protects against cholinergic deficits, in The Proceedings of the 44th Oholo Conference: The Blood Brain Barrier Drug Delivery and Brain Pathology, Lustig S., Shapira S., Kobiler O., eds., Plenum Press, New York, NY, pp. 363-370.
10. Gressens P., Hill J. M., Gozes I., Fridkin M., and Brenneman D. E. (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155-158.
11. Leker R. R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D. E., Fridkin M., et al. (2002) NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33, 1085-1092.
12. Newton P., Brenneman D. E., and Gozes I. (2001) 30-Day intranasal toxicity studies of NAP in rats and dogs. J. Mol. Neurosci. Abstr. 16, 61.
13. Newton P., Spier A. D., and Gozes I (2003) Intravenous and intranasal toxicity and toxicokinetic study of NAPVSIPQ (NAP) in dogs. Neuropeptides (Abstr.) 37, 163.
14. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D. E., and Gozes I. (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854, 257-262.
15. Pike C. J., Burdick D., Walencewicz A .J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13, 1676-1687.
16. Pinhasor A., Mandel S., Torchinsky A., et al., (2003) Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 144, 83-90.
17. Poduslo J. F., Curran G. L., Kumar A., Frangione B., and Soto C. (1999) β-Sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain-barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol. 39, 371-382.
18. Romano J., Beni-Adani L., Levy Nissenbaum O., Brenneman D. E., Shohami E., and Gozes I. (2002) A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene atlas array analysis. J. Mol. Neurosci. 18, 137-450.
19. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
20. Shoji M., Golde T. E., Ghiso J., Cheung T. T., Estus S., Shaffer L. M., et al. (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129.
21. Sigalov E., Fridkin M., Brenneman D. E., and Gozes I. (2000) VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J. Mol. Neurosci. 15, 147-154.
22. Soto C. (1999) Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today. 5, 343-350.
23. Soto C., Kascsak R. J., Saborio G. P., Aucouturier P., Wisniewski T., Prelli F., et al. (2000) Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet. 355, 192-197.
24. Spong C. Y., Abebe D. T., Gozes I., Brenneman D. E., and Hill J. M. (2001) Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J. Pharmacol. Exp. Ther. 297, 774-779.
25. Steingart R. A., Solomon B., Brenneman D. E., Fridkin M., and Gozes I. (2000) VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 15, 137-145.
26. Tamagno E., Parola M., Guglielmotto M., Santoro G., Bardini P., Marra L., et al. (2003) Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med., 35(1), 45-58.
27. 2, caspase-3, NF-κB, p53 and c-Jun. Neurotoxicology 23(3), 351-365.
28. Wilkemeyer M. F., Chen S. Y., Menkari C. E., Brenneman D. E., Sulik K. K., and Charness M. E. (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc. Natl. Acad. Sci. U. S. A. 100(14), 8543-8548.
29. Zaltzman R., Beni S. M., Giladi E., Pinhasov A., Steingart R. A., Romano J., et al. (2003) Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury related dysfunction in adults. Neuroreport 14, 481-484.
30. Zamostiano R., Pinhasov A., Gelber E., Steingart R. A., Seroussi E., Giladi E., et al. (2001) Cloning and characterization of the human activity-dependent neuroprotective protein (ADNP). J. Biol. Chem. 276, 708-714.
31. Zemlyak I., Furman S., Brenneman D. E., and Gozes I. (2000) A novel peptide (NAP) prevents death in enriched neuronal cultures. Regul. Pept. 96, 39-43.